Aimmune Therapeutics, Inc.

Home » Aimmune Therapeutics, Inc.

Secondary

Aimmune Therapeutics, Inc.

They are a clinical-stage biopharmaceutical company developing treatments for potentially life-threatening food allergies.

Symbol

AIMT

Last Closing Price
$32.21

Shares
4,300,000

Effective Date
February 22, 2018

Underwriters
BofA Merrill Lynch, Cantor Fitzgerald, Piper Jaffray, Credit Suisse, RBC Capital Markets

To view the prospectus for Aimmune Therapeutics, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253